Sarepta Therapeutics, Inc. SRPT
15.13 USD -0.94 (-5.85%)
Regular-session close
15.20 +0.07 +0.46%
After hours · Nov 16, 6:47 PM ET
15.06 Day range 16.00
14.68 52-week range 24.68
- YTD
- -29.69%
- 1 year
- -19.56%
News
247wallst.com Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More A two-day rally built partly on short covering faces its first real test when October inflation data lands at 8:30 ET. Meanwhile, analysts flipped hard on Wix and DraftKings, while a surprise double…
marketbeat.com Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance Sarepta Therapeutics NASDAQ: SRPT expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy…benzinga.com RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18 RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and raises the price target from $17 to $18.
benzinga.com Sarepta Therapeutics Q3 2026 Earnings Call Transcript Sarepta Therapeutics (NASDAQ:SRPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Sarepta Therapeutics Q3 Adj. EPS $0.13 Beats $0.06 Estimate, Sales $381.400M Beat $352.961M Estimate Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116.67 percent. This is a 200 percent increase over losses of…
